FAIRFIELD, New Jersey, March 13 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it did not issue, authorize or approve the press release titled "Stonegate Report About Unigene Laboratories Inc.", which was released yesterday. Pursuant to the Company's policies and procedures, Unigene does not endorse, confirm, validate or otherwise comment on reports issued by analysts and unrelated third parties. Any opinions, estimates or forecasts regarding Unigene's performance made by analysts or other third parties are theirs alone and do not represent the opinions, estimates, forecasts or predictions of Unigene or its management.

About Unigene

The aim of the ‘Symbiotic Evolutionary Robot Organisms’ project, or ‘Symbrion’, is to understand the principles that govern how robots can form themselves into a single artificial organism. The technique enables them to interact collectively with the physical world, and might ultimately be applied to real-world tasks such as rescuing earthquake victims.

‘Multi-robot organisms’ are made up of large swarms of individual robots, each slightly larger than a sugar cube, which work together to form a single artificial life-form. The organisms are able to share information and energy with one another, and to manage their own hardware and software.

LONDON, March 13 /PRNewswire/ --

The 13 members of the Organization of Petroleum Exporting Countries (OPEC) pumped an average 32.33 million barrels per day (b/d) of crude oil in February, an 80,000 b/d increase on January levels, according to a Platts (http://www.platts.com/) survey of OPEC and oil industry officials just released.

However, production from the 12 countries, excluding Iraq, bound by output allocations fell to 29.93 million b/d in February from 29.96 million b/d in January, the survey showed.

North American buildings release more than 2,200 megatons of CO2 into the atmosphere - 35 percent of the continent’s total - according to a new report issued by the trinational Commission for Environmental Cooperation (CEC). The report says rapid market uptake of energy-saving technologies could result in over 1,700 fewer megatons of CO2 emissions by 2030 - a cut nearly equal to the CO2 emitted by the entire US transportation sector in 2000.

Promoting the green design, construction, renovation and operation of advanced energy-saving buildings could cut North American greenhouse gas emissions more deeply and cheaply than any other available measure, the report advises.

LEUVEN, Belgium, March 13 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the twelve month period ending 31 December 2007. During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights

Scientists are fond of placing great value on what they call skepticism: Not taking things on faith. Science versus religion, is the point. In practice this means wondering about the evidence behind this or that statement, rather than believing it because an authority figure said it. A better term for this attitude would be: Value data.

Due to a recent whirlwind bout of touring, I was excited to do nothing but plunk on my couch with the dog and watch many, many hours of pro sports. Ski videos would be nice, but really what I was looking for was a good cricket match — completely incomprehensible and hopefully extending across multiple days. Contract bridge and international chess competed for close-second.

This has happened before but, if you have small children and/or a pregnant spouse, you know your ability to sink into a vegetative stupor is tempered by relationship politics. This, I think, is not an issue relevant to me alone.

LONDON, March 13 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) today announces a collaboration with AstraZeneca (LSE: AZN), focused on the development of a range of novel approaches for the delivery of siRNA molecules. The deal builds on Silence Therapeutics' leading expertise in the delivery of siRNA molecules, in particular its success with the functional systemic delivery of siRNA in vivo using its proprietary AtuPLEX technology. The financial details of this collaboration, in which both parties will contribute expertise and know-how, have not been disclosed.

This new deal is independent of the parties' three-year collaboration signed in July 2007, whose aim is to develop novel siRNA therapeutics against specific targets exclusive to AstraZeneca.

BRADFORD, England, March 13 /PRNewswire/ -- Health researchers at the University of Bradford have welcomed the GBP500,000 donation announced by best-selling author Terry Pratchett today (Thursday 13 March 2008).

Mr Pratchett was diagnosed with a rare early-onset form of Alzheimer's disease in December last year. He will announce a pledge of around GBP494,000 at the Alzheimer's Research Trust annual conference.

Currently there are around 15,000 people in the UK with early-onset dementia, which strikes under the age of 65.